The Safety of an Adenosine A 1 -Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment: Findings from PROTECT

Author： Teerlink John R.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.35, Iss.3, 2012-03, pp. : 233-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure

By Slawsky Mara T   Givertz Michael M  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 2, 2009-02 ,pp. : 311-322

Informa Healthcare

Access to resources Recommend Favorite

BG 9928, an oral A1 adenosine antagonist, shows promise for patients with heart failure

By  

Inpharma, Vol. 1, Iss. 1601, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Renal Effects of Adenosine A-Receptor Antagonists in Congestive Heart Failure

By Gottlieb S.S.  

Drugs, Vol. 61, Iss. 10, 2001-01 ,pp. : 1387-1393

Adis International

Access to resources Recommend Favorite

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

By Bauman John  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 662-671

Springer Publishing Company

Access to resources Recommend Favorite

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V 1A and V 2 receptor antagonist, in dogs with pacing-induced congestive heart failure

By Yatsu T.   Tomura Y.   Tahara A.   Wada K.-i.   Kusayama T.   Tsukada J.   Tokioka T.   Uchida W.   Inagaki O.   Iizumi Y.   Tanaka A.   Honda K.  

European Journal of Pharmacology, Vol. 376, Iss. 3, 1999-07 ,pp. : 239-246

Elsevier

Access to resources Recommend Favorite